Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study examined the efficacy/effectiveness of pazopanib and trabectedin in previously treated metastatic synovial sarcoma (mSS). A literature search identified studies (2002-2019) reporting outcomes of pazopanib and trabectedin in previously treated mSS, including median overall survival (mOS) and overall response rate (ORR). A meta-analysis was conducted and sensitivity analyses examined outcomes by agent (pazopanib/trabectedin), study type (clinical trial [CT] or real-world [RW]) and sample size. Sixteen studies were included (pazopanib: n = 7; trabectedin: n = 9). Pooled mOS was 10.4 months and was consistent across agents and in RW and CT (pazopanib: 10.3; trabectedin: 10.4; CT: 10.8; RW: 9.9). ORR results were more variable (pooled ORR: 14.7%). ORR was consistently higher for RW (17.7%) than for CT (9.5%) and for pazopanib (18.9%) compared with trabectedin (12.3%). Poor outcomes across agents and settings highlight a need for novel treatments with improved efficacy. This study serves as a benchmark for efficacy estimates in this rare disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2022-0348 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.
Cancer Med
August 2025
Department of Medical Oncology, Centre Oscar-Lambret, Lille, France.
Background: Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting.
Methods: We conducted a retrospective study in five expert centers to compare the progression-free survival (PFS) and overall survival (OS) of patients with advanced L-Sarcomas (liposarcomas or leiomyosarcoma) according to the RDI calculated over the first three cycles (RDI < 80% and RDI ≥ 80%).
Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review.
Anticancer Drugs
August 2025
Osteoncologia, Sarcomi ossei e dei Tessuti Molli e Terapie Innovative, IRCCS Istituto Ortopedico Rizzoli.
Malignant peripheral nerve sheath tumors (MPNSTs) are rare and have among the worst prognoses among all soft tissue sarcomas, with 5-year overall survival rates ranging from 16 to 52%. We report a case of a 50-year-old man with localized dorsal MPNST who developed local recurrence after 1 year and lung metastasis 3 years after diagnosis. He underwent primary tumor resection, two resections for local recurrence, one lung metastasectomy, seven lines of chemotherapy (epirubicin-ifosfamide, cisplatin-etoposide, trabectedin, pazopanib, carboplatin-etoposide, gemcitabine, and ifosfamide), and four courses of stereotactic body radiotherapy for lung metastases.
View Article and Find Full Text PDFTreatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy.
Int J Clin Oncol
May 2025
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Synovial sarcoma (SS) is the most common soft tissue sarcoma in children and adolescents. Despite the availability of new agents such as pazopanib and trabectedin, the prognosis after recurrence remains poor. Adoptive cell therapy is an emerging therapeutic strategy based on the modulation, manipulation, and selection of autologous T-cells in vitro to overcome immune system tolerance to tumor cells.
View Article and Find Full Text PDFConfirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal sarcoma: A case report.
Oncol Lett
March 2025
Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present case report describes a tumor in a 55-year-old man that was originally thought to be a Ewing-like adamantinoma, but was recently found to be an sarcoma following direct sequencing.
View Article and Find Full Text PDFLow-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
ESMO Open
September 2024
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:
Article Synopsis
- A retrospective study by the Ultra-Rare Sarcoma Working Group analyzed data from 101 patients with metastatic low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid (H)-LGFMS/SEF across 28 centers from January 2000 to September 2022.
- The study measured progression-free survival (PFS) from the detection of metastasis and after starting treatment, revealing varying effectiveness among the different sarcoma types and treatments.
- Findings showed that metastatic LGFMS and SEF had distinct survival outcomes, with systemic treatments showing limited effectiveness, suggesting a need for new therapeutic options in future research.